Efficacy and Safety of CT-Guided I-125 Seed Implantation for Advanced Pancreatic Cancer: A Meta-Analysis

Hao Wang,Haitao Wang,Xiaodong Huo,Bin Huo,Shude Chai,Lei Wang,Lili Wang,Li Zang,Dingkun Hou,Jinhuan Wang,Qiang Cao

DOI: https://doi.org/10.1016/j.brachy.2017.04.166

IF: 2.441

2017-01-01

Brachytherapy

Abstract:To systematically evaluate the efficacy and safety of I-125 seed implantation for advanced pancreatic cancer.

What problem does this paper attempt to address?

Efficacy and Safety of CT-guided 125I Seed Implantation for Treatment of Advanced Pancreatic Cancer: a Meta-analysis

Wang Hao,Huo Bin,Huo Xiaodong,Wang Lili,Hou Dingkun,Zang Li,Wang Jinhuan,Chai Shude,Wang Junjie,Wang Haitao

DOI: https://doi.org/10.3760/cma.j.issn.0254-5098.2017.07.014

2017-01-01

Abstract:Objective To systematically evaluate the efficacy and safety of 125I seed implantation for treatment of advanced pancreatic cancer.Methods An electronic literatuire search was performed about randomized controlled trials(RCTs) of 125I implantation for treamtent of advanced pancreatic cancer in CNKI,Wanfang Data,CBM,Cochrane Library,PubMed and Embase (from the date of building the database to November 2016).Two investigators independently screened literature,extracted data and assessed the risk bias of included studies,and the Meta-analysis was performed by using Revman 5.3software.Results There were 12 RCTs (n =689) included.Meta-analysis showed that the objective respond rate(ORR) (OR =3.24,95％CI2.33-4.52,P＜0.001),the 6-month survival rate(OR =3.61,95％ CI 1.53-8.52,P =0.003),the 12-month survival rate(OR =4.80,95％ CI 2.40-9.57,P ＜ 0.001) and the relief rate of pain were higher than those in the control group.However,there were no significant differences between both groups in the 2-year survival rate and the adverse reaction rate,which were (OR=2.36,95％ CI 0.47-11.74,P =0.29) and (OR =4.94,95％ CI 1.05-23.23,P =0.04),respectively.Conclusions The limited current evidence showed that 125I implantation for treatment of advanced pancreatic cancer is effective and safety.125I implantation can improve the ORR,short-time survival rate and pain relief rate.In addition,there was no significant increase in the incidence of related adverse events except for seed malposition.Although the quality and quantity of evidences is limited,it merits further study to provide high quality evidences.
Percutaneous CT-Guided Iodine-125 Seeds Implantation for Unresectable Pancreatic Cancer

Bin Liu,Tong Zhou,Junjie Wang,Fujun Zhang,Yuliang Li

DOI: https://doi.org/10.1016/j.brachy.2016.04.246

IF: 2.441

2016-01-01

Brachytherapy

Abstract:To examine the safety and clinical efficacy of CT-guided radioactive iodine-125 (125I) seeds implantation for patients with unresectable pancreatic cancer. A group of 26 patients with pathologically confirmed unresectable pancreatic cancer underwent percutaneous CT-guided 125I seeds implantation (Figure 1). Part of them received transarterial chemotherapy and/or percutaneous transhepatic cholangial drainage (PTCD) before or after seeds implantation. The number of seeds implanted ranged from 30-80, with a median of 53. Specific activity of the seeds ranged from 0.6-0.8mCi. The minimal peripheral dose of 125I seeds was 110-130Gy (median 115Gy). The primary endpoints were the objective response rates, local control rates, and overall survival (OS). CT scan 2 months after treatment revealed complete response (CR) in 8 patients, partial response (PR) in 9 patients. Overall response rate (CR+PR) is 65.38%. Local control rare was 88.46%. Median survival of the whole group was 15.3 months, while for stage III and stage IV was 17.6 and 9.1 months, respectively. The estimated 1-year survival was 30.77%. Median survival for pure seeds implantation is 10.7 months. There is no significant difference between the seeds group and seeds-drug/PTCD combined group in terms of median survival time. Fever high than 39.0 centi-degree, upper gastrointestinal bleeding or perforation, pancreatitis, pancreatic fistula, radiation enteritis or cholangiolitis appeared in no patient. We consider CT-guided 125I seeds implantation as a safe, effective, uncomplicated treatment for unresectable pancreatic cancer.
Therapeutic Effect of CT-guided 125I Seed Implantation on Advanced Lung Cancer and Pulmonary Metastatic Carcinoma

Yiqing Wang,Linhai Zhu,Xu Lin,Cheng He,Zhou An,Jie Tang,Wang Lv,Jian Hu

DOI: https://doi.org/10.3779/j.issn.1009-3419.2020.103.04

2020-01-01

Abstract:BACKGROUND:Primary lung cancer and metastatic lung cancer are common malignant tumors of the lung and are the main cause of cancer-related death. Advanced lung cancer and lung metastatic cancer are mainly treated by systemic therapy, and local treatment is also an effective treatment for the refractory or recurrent lesions in the lungs after systemic treatment. ¹²⁵I radioactive particle implantation, as an efficient conformal radiotherapy, has a certain control effect on localized lung cancer. The purpose of this study was to investigate the clinical efficacy and safety of computed tomography (CT) guided percutaneous puncture of lung tissue with ¹²⁵I radioactive particle implantation in the treatment of advanced lung cancer and lung metastatic cancer.METHODS:Continuouslycollectedthe clinical and pathological data of 105 patients with advanced lung cancer and metastatic lung cancer treated by ¹²⁵I radioactive seed implantation in the Department of Thoracic Surgery, First Affiliated Hospital of Zhejiang University School of Medicine from January 1, 2014 to November 30, 2018. The patients were followed until March, 2019. The clinical efficacy and complications of seedimplantation were analyzed.RESULTS:A total of 105 patients were included in the study, 78 patients with advanced lung cancer and 27 patients with lung metastases. The median survival time after seed therapy was 395 days. The 1-year survival rate was about 78.1%, and the 2-year survival rate was about 56.1%. Seed implantation for advanced lung cancer is equivalent to lung metastasis. Seed combined with radiofrequency ablation, microwave ablation, and chemotherapy did not improve seed treatment. However, particle combined with external radiation therapy has a significant survival disadvantage compared with simple seed therapy.CONCLUSIONS:The CT-guided ¹²⁵I radioactive seed implantation has controllable complications and can be used as a safe and effective treatment for advanced lung cancer and lung metastases.
Safety and Effectiveness Analysis of Percutaneous Microwave Thermal Ablation Therapy Combined Brachytherapy for Lung Malignant Lesion

Cheng He,Linhai Zhu,Xu Lin,Zhou An,Wang Lv,Jian Hu

DOI: https://doi.org/10.3779/j.issn.1009-3419.2020.102.06

2020-01-01

Abstract:BACKGROUND:Microwave ablation and radioactive seed implantation are therapeutic options for patients with advanced lung cancer and lung metastases lesion who are not surgical candidates. However, reports on therapeutic effectiveness and safety of the two combination treatments methods have been limited to small case series. This research was to assess the clinical outcome and safety of radioactive seed implantation combined with computed tomography (CT)-guided microwave ablation for the treatment of advanced lung cancer and lung metastases lesion.METHODS:The clinical data of 21 advanced lung cancer and lung metastases patients who received treatment at author hospital during the period from May 2018 to December 2018 were retrospectively analyzed. The patients were divided into two groups by whether received extra percutaneous microwave thermal ablation therapy. The short-term effectiveness and safety were analyzed.RESULTS:The efficacy of control group was 28.75%, and the efficacy of experiment group was 14.28%. The rate of adverse reaction between two groups has no significantly difference (P>0.05).CONCLUSIONS:Seed implantation combined with CT-guided microwave ablation for advanced lung cancer and lung metastases is safety and effective.
Analysis of the Efficacy of Transcatheter Arterial Infusion Chemotherapy in the Treatment of Pancreatic Carcinoma

Chunhui Nie,Yuelin Zhang,Guanhui Zhou,Tanyang Zhou,Tongyin Zhu,Baoquan Wang,Shengqun Chen,Hongliang Wang,Ziniu Yu,Li Jing,Junhui Sun

DOI: https://doi.org/10.1016/j.jimed.2020.10.005

2021-01-01

Journal of Interventional Medicine

Abstract:OBJECTIVE:To evaluate the clinical efficacy of infusion of gemcitabine (GEM) and fluorouracil (5-FU)through the celiac artery and superior mesenteric artery in the treatment of pancreatic carcinoma (PC).METHODS:We analyzed 20 patients diagnosed clinically or pathologically with PC, without metastases, who had an estimated survival duration of >3 months in our department from May 2009 to December 2014. Nine patients were treated directly without surgical resection of the tumor, while the other 11 patients were treated after surgery. In all patients, the femoral artery was punctured using the Seldinger technique, and a catheter was placed in the opening of the celiac artery or the superior mesenteric artery. We administered 500 mg/m2 GEM and 500 mg/m2 5-FU. Observational data included data on clinical efficacy and survival rates during the follow-up period of 3-72 months.RESULTS:Twenty patients were treated 85 times with transcatheter arterial infusion chemotherapy (TAI). The survival rates were 80%, 40%, 35%, 20%, 10%, and 5% at 3, 6, 12, 24, and 72 months, respectively.CONCLUSION:TAI chemotherapy with GEM and 5-FU may be a therapeutic option for the treatment of PC.
Ultrasound-guided interstitial ~(125)I seed implantation in the treatment of locally advanced pancreatic carcinoma

Bai Jing,Wang Junjie,Xiu Dianrong

DOI: https://doi.org/10.3969/j.issn.1009-6604.2006.05.017

2006-01-01

Abstract:Objective To investigate the feasibility and efficacy of ultrasound-guided interstitial implantation of radioactive ~(125)I seed for the treatment of unresectable pancreatic carcinoma.Methods Twenty-one patients with unresectable primary pancreatic carcinoma were treated with interstitial ~(125)I seed implantation under laparotomy.The radioactive activity and the number of implanted seed were determined according to preoperative CT scanning outcomes by using the Treatment Planning System(TPS).The matched peripheral dose(MPD) was 65~110 Gy.The radioactive activity ranged 0.4~0.5 mCi per seed.A total of 10~75 ~(125)I seed were implanted with an 18-gauge seed needle and the Mick applicator under direct visualization or ultrasound guidance.Gastroenterostomy or cholangiojejunostomy were performed in 8 patients before or after the implantation.Postoperative external radiation therapy combined with chemotherapy with gemcitabine was carried out in 2 patients. Stent placement was conducted in 2 patients preoperatively and postoperatively, respectively.Results Out of 15 patients with abdominal pain,complete and partial pain relief were obtained in 7 patients and 7 patients,respectively,at 1~3 postoperative days,the response rate being 93.3%(14/15). Except for 2 cases of loss of follow-up,there were 5 cases of complete response(CR),7 cases of partial response(PR),5 cases of progressive disease(PD),and 2 cases of no change(NC).Of 19 patients,the median survival time was 5 months and the 1-year survival rate was 26.3%.Chylous leakage occurred in 1 patient and seed dislodgement to the liver occurred in 3 patients.No pancreatic fistula or pancreatitis were encountered. Conclusions Radioactive ~(125)I seed implantation for the treatment of pancreatic carcinoma is safe,effective,and micro-invasive,being a good option of remedy.
Efficacy Analysis of Chemotherapy in Combination with 125I Seed Implantation for Treatment of Inoperational Pancoast Tumor

Yan Weiliang,Huo Xiaodong,Huo Bin,Wang Haitao,Zheng Guangjun,Shi Shuyuan,Feng Zhen,Chai Shude,Wang Junjie

DOI: https://doi.org/10.3760/cma.j.issn.0254-5098.2017.12.006

2017-01-01

Abstract:Objective To explore the therapeutic effect of radioactive 125I seeds combined with chemotherapy on the treatment of inoperative pancoast tumor by CT-guided percutaneous implantation of treatment planning system (TPS).Methods From December 2002 to December 2010,36 patients with pancoast tumor were confirmed by imaging and pathology.Among them,26 cases suffered from squamous cell carcinoma and 10 cases with adenocarcinoma.At 1 week after radioactive 125I implantation,chemotherapy was administered as intravenous 1 000 mg / m2 gemcitabine at 1 and 8 d and intravenous cisplatin 75 mg/ m2 at 1 d for 4 consecutive cycles.The prescribed dose (PD) was 120 Gy,and the median activity of the seeds was 0.7 mCi (2.59 × 107 Bq) with the range of 0.68-0.82 mCi (2.52 × 107-3.03 × 107 Bq).The patients were followed-up and the median follow-up time was 48 months.The survival rate was observed.Results The mPD of the target tumor was (118.7 ± 7.2) Gy,D90(126 ± 4.7) Gy,D90 ＞ mPD.The rate of CR (11 cases) was 63.6％,and the effective rate (CR + PR) was 83.4％.The follow-up last till December 1st,2016.1-,3-and 5-year local control rates were 92％,83％,and 67％,respectively.1-,3-and 5-year cumulative survival rate were 84.1％,56.7％,and 36.8％,respectively.Median survival was 38 months.Conclusions Chemotherapy combined with tissue radioactive 125I seed implantation is a minimally invasive and effective method for the treatment of pancoast tumor.
Iodine-125 Seed Implantation for Unresectable Pancreatic Carcinoma Guided by Intraoperative Ultrasound

王俊杰,修典荣,冉维强,白静,朱丽红,刘江平

DOI: https://doi.org/10.3760/cma.j.issn.0254-5098.2005.05.011

2005-01-01

Abstract:Objective To investigate the surgical technique,efficacy and side effects of 125Ⅰ seed interstitial implantation for pancreatic carcinoma. Methods A total of 22 patients with biopsy proven unresectable adenocarcinoma of pancreas were treated with 125Ⅰ implants during laparotomy. Of them 11 patients were treated previously by a combination of bypass surgery. The stent was implanted in 2 cases 2 weeks before and 4 weeks after seed implantation. Seed needles were implanted parallelly to each other,with 1-1.5 cm apart. Mick applicator was being connected to each needle to implant seed. The radioactive activity ranged 0.40-0.70 mCi,the matched peripheral doses were 65-145 Gy. The mean number of 125Ⅰ seed was 11-78. Five cases received external beam irradiation with 3D-CRT, the doses were 39-70 Gy and 5 patients received 2 cycle of gemcitabine chemotherapy at 1000 mg/m 2 on dl and d8. Results Pain was completely relieved in 12 cases,partially relieved in 2 cases,and no response was noted in one case, so the response rate was 93.33%. The median time was 2-3 d.Altogethe 27.27% of the cases died from local recurrence of pancreatic carcinoma and 50% from metastasis. The median survival time in these patients was 6 months,with a 2-year survival rate of 9.09%. The seed immigrated to liver in 3 cases.There were no serious side effects such as infection,pancreatitis,pancreatic fistula,etc. Conclusion Radioactive seed implantation was safe,high local control,mini-damage,satisfactory palliation of pain and without significant complications.
Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma

Junjie Wang,Yuliang Jiang,Jinna Li,Suqing Tian,Weiqiang Ran,Dianrong Xiu

DOI: https://doi.org/10.1186/1756-9966-28-88

IF: 12.658

2009-01-01

Journal of Experimental & Clinical Cancer Research

Abstract:Background To assess the feasibility and efficacy of using 125 I seed implantation under intraoperative ultrasound guidance for unresectable pancreatic carcinoma. Methods Fourteen patients with pancreatic carcinoma that underwent laparotomy and considered unresectable were included in this study. Nine patients were pathologically diagnosed with Stage II disease, five patients with Stage III disease. Fourteen patients were treated with 125 I seed implantation guided by intraoperative ultrasound and received D 90 of 125 I seeds ranging from 60 to 140 Gy with a median of 120 Gy. Five patients received an additional 35–50 Gy from external beam radiotherapy after seed implantation and six patients received 2–6 cycles of chemotherapy. Results 87.5% (7/8) of patients received partial to complete pain relief. The response rate of tumor was 78.6%, One-, two-and three-year survival rates were 33.9% and 16.9%, 7.8%, with local control of disease achieved in 78.6% (11/14), and the median survival was 10 months (95% CI: 7.7–12.3). Conclusion There were no deaths related to 125 I seed implant. In this preliminary investigation, 125 I seed implant provided excellent palliation of pain relief, local control and prolong the survival of patients with stage II and III disease to some extent.
CT-MPR Guides Percutaneous Brachytherapy Easily for Hepatic Carcinoma and Extrahepatic Metastases

Tong-Yin Zhu,Jun-Hui Sun,Guan-Hui Zhou,Yue-Lin Zhang,Chun-Hui Nie,Tan-Yang Zhou,Bao-Quan Wang,Sheng-Qun Chen,Zi-Niu Yu,Hong-Liang Wang

DOI: https://doi.org/10.1016/j.brachy.2018.04.185

IF: 2.441

2018-01-01

Brachytherapy

Abstract:This study was aimed to evaluate the feasibility and safety of CT-MPR guided percutaneous iodine-125 implantation for hepatic carcinoma and extrahepatic metastases.
Efficacy and safety of 3D printing coplanar template-assisted iodine-125 seed implantation as palliative treatment for inoperable pancreatic cancer

Baohu Wang,Bin Qiu,Linlin Wu,Yu’e Liu,Jingxian Zhang,Ruoyu Wang,Kaixian Zhang,Junjie Wang

DOI: https://doi.org/10.5114/jcb.2022.114990

2022-01-01

Journal of Contemporary Brachytherapy

Abstract:Purpose: To investigate clinical efficacy and safety of 3D printing coplanar template-assisted iodine-125 (125I) seed implantation as a palliative treatment for inoperable pancreatic cancer.Material and methods: Consecutive 28 patients (16 males and 12 females, median age of 64 years) with histologically diagnosed pancreatic cancer who underwent 3D printing coplanar template-assisted 125I seed implantation between June 2016 and May 2019 were analyzed. Among these 28 patients, 9 (32.1%) and 19 (67.9%) patients were presenting with tumor node metastasis (TNM) stage IIB and stage III cancer, respectively. Seed implantation was conducted for pain palliation intent in 25 patients and recurrent cancer after radiotherapy in 3 patients.Results: No significant differences were found between pre-planned and post-operative dosimetric parameters, involving D90, D100, V90, V100, V150, conformity index, external index, and homogeneity index (all p > 0.05). Two months after implantation, pain relief rate was 76% (19/25) for pain patients. Overall tumor response rate (complete response + partial response) was 60.7% (complete response 0 patients, partial response 17 patients, stable disease 8 patients, and progressive disease 3 patients). Median survival was 10.5 months and estimated 1-year survival rate was 26.7%. Only one patient presented with a slightly upper gastro-intestinal hemorrhage, and another patient suffered from incomplete intestinal obstruction soon after implantation, both recovered after conservative medical treatment without a prolonged hospital stay. No major complication was observed.Conclusions: 3D printing coplanar template-assisted 125I seed implantation appears to be safe and effective palliative treatment for inoperable pancreatic cancer with favorable clinical outcomes.

oncology,radiology, nuclear medicine & medical imaging
Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials

Mengting Tong,Jing Wang,Hongliang Zhang,Haibo Xing,Yanling Wang,Yong Fang,Hongming Pan,Da Li

DOI: https://doi.org/10.7150/jca.26672

IF: 3.9

2019-01-01

Journal of Cancer

Abstract:Purpose: Pancreatic cancer is a common digestive neoplasm with a high fatality rate. We performed this systematic review and meta-analysis of clinical randomized phase III trials to explore the efficacy and safety of gemcitabine plus anti-angiogenesis therapy versus gemcitabine monotherapy for locally advanced or metastatic pancreatic cancer. Methods: We searched PubMed, Embase and the Cochrane Library to identify eligible studies. Data were collected for the period from January 1, 2000 to August 20, 2018. Hazard ratios (HRs) and odds ratios (ORs) were used as main evaluation parameters. Results: A total of eight eligible studies with 3,586 individuals were included in the present meta-analysis. The results showed that the combination of gemcitabine plus anti-angiogenesis therapy had a significant effect on progression-free survival (HR = 0.92, 95% CI: 0.86 - 1.00, P = 0.04), but led to no significant difference in the overall survival (HR = 0.96, 95% CI: 0.88 - 1.05, P = 0.38). In terms of safety, gemcitabine plus anti-angiogenesis therapy did not increase the rate of grade 3-4 common adverse effects except for hypertension. Conclusions: Although gemcitabine plus anti-angiogenesis therapy might prolong the progression-free survival in locally advanced or metastatic pancreatic cancer, these successful results did not translate into a significant improvement in the overall survival or change in the clinical guidelines.
Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

Haiyang Xie

2010-01-01

Abstract:Objective To discuss the therapeutic effect of CT-guided 125I seed implantation combined with transcatheter arterial chemoembolization(TACE) for the treatment of portal vein tumor thrombus(PVTT) associated with hepatocellular carcinoma(HCC).Methods A total of 58 patients with confirmed HCC accompanied by PVTT were enrolled in this study.Of the 58 patients,CT-guided 125I seed implantation together with TACE was performed in 26(group A),while only TACE was employed in 32(group B).The clinical data were retrospectively analyzed and the therapeutic results were compared between two groups.Results For group A,the one-year and two-year survival rate was 42.3% and 23.0% respectively,with a mean survival time of 15.5 months.Of the 26 patients in group A,the complete remission(CR) was obtained in 3,partial remission(PR) in 9,with a total effective rate(CR + PR) of 46.2%(12 /26).While in group B,the one-year and two-year survival rate was 21.9% and 6.3% respectively,with a mean survival time of 7.5 months.And CR was obtained in 2 cases,PR in 6 cases,with a total effective rate(CR + PR) of 25%(8/32).Both the survival rate and the total effectiveness of group A were significant higher than that of group B(P 0.05).Conclusion As a minimally-invasive technique with less sufferings and fewer complications,CT guided 125I seed implantation combined with transcatheter arterial chemoembolization can markedly improve the therapeutic effect for portal vein tumor thrombus associated with hepatocellular carcinoma.
The Investigation of 125I Seed Implantation As a Salvage Modality for Unresectable Pancreatic Carcinoma.

Hao Wang,Junjie Wang,Yuliang Jiang,Jinna Li,Suqing Tian,Weiqiang Ran,Dianrong Xiu,Yang Gao

DOI: https://doi.org/10.1186/1756-9966-32-106

IF: 2.441

2014-01-01

Brachytherapy

Abstract:To assess the efficacy of intraoperative ultrasound-guided implantation of 125I seeds for the treatment of unresectable pancreatic carcinoma, and analyze the associated prognostic factors.
Clinical Studies of Pancreatic Cancer Treated by Endovascular Implantation of Iodine-125 Seeds Strand

Linlin Wu,Kaixian Zhang,Zhiping Yan,Jianjun Luo

DOI: https://doi.org/10.1016/j.brachy.2016.04.243

IF: 2.441

2016-01-01

Brachytherapy

Abstract:To Study the safety and efficacy of advanced pancreatic cancer treated by endovascular implantation of Iodine-125 (125I) seeds strand. 12 patients with advanced pancreatic cancer diagnosed by medical imaging department of Zhongshan Hospital complicated with SMV or SV affected. The second-order branch of intrahepatic portal vein was punctured transhepatically under ultrasound guidance. Two 0.035-inch wires were inserted into the splenic vein or superior mesenteric vein. The stent and I125 seed strand was inserted to the target position. Finally, the transhepatic puncture track was occluded by coils. Regional arterial infusion chemotherapy of pancreatic cancer were needed. Procedure-related adverse events were compared before and after operation. Values were expressed as mean +standard deviation. Changes in values before and after therapy were analyzed by the paired Student t test. Survival were calculated by the Kaplan-Meier test. Technical success rate was 100% for placement of 125I seeds strands in the vascular. No serious procedure-related adverse events occurred. Postoperative particles dose verification, V50 range is: 74.66% + 5.15%. Results of laboratory tests obtained 30 days after the procedure showed no significant difference compared with test results before therapy. No serious procedure-related complications, such as hepatic failure or myelosuppression. During the follow-up period, the tumor activity and size decreased. During the follow-up period, 11 patients died, 1 patient survival. The longest survival time was 17 months, the shortest time was 4 months. The average survival time was 12+2.36 months and the median survival time was 10.73+1.40 months. Early pancreatic cancer peripheral vascular infringement and early transfer occurs, thus high malignant degree, require multidisciplinary joint efforts, to achieve advances in treatment. Regional arterial infusion chemotherapy of pancreatic cancer is one of commonly used treatment of pancreatic cancer in late, but within the portal system into particle was still in the stage of exploration, for the treatment of pancreatic cancer this paper proposes a new clinical thought and method.
The efficacy of coaxial percutaneous iodine-125 seed implantation combined with arterial infusion chemotherapy for advanced pancreatic cancer: a randomized clinical trial

HongXiang YaoYing ZhuGeShiXiang JinShuiBing ChenHengYiTing ZhangDong ZhangZhiGang ChenThe Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University,Wenzhou,ChinaHongXiang Yao is a Professor of interventional medicine at the Second Affiliated Hospital of Wenzhou Medical University.Ying ZhuGe is the Deputy Director of the Skills Training Center at the Second Affiliated Hospital of Wenzhou Medical University.ShiXiang Jin is a Professor of interventional medicine at the Second Affiliated Hospital of Wenzhou Medical University.ShuiBing Chen,MD,is the attending physician of the Interventional Medicine Department at the Second Affiliated Hospital of Wenzhou Medical University.HengYiTing Zhang,MD,is the attending physician of the Interventional Medicine Department at the Second Affiliated Hospital of Wenzhou Medical University.Dong Zhang is a physician in the Interventional Medicine Department of the Second Affiliated Hospital of Wenzhou Medical University.ZhiGang Chen,MD,is a physician in the Interventional Medicine Department of the Second Affiliated Hospital of Wenzhou Medical University.

DOI: https://doi.org/10.1080/09553002.2024.2347357

2024-05-01

International Journal of Radiation Biology

Abstract:Background This study aimed to evaluate the clinical efficacy of coaxial percutaneous Iodine-125 ( 125 I) seed implantation in combination with arterial infusion chemotherapy for the treatment of advanced pancreatic cancer (PC) through a randomized controlled trial.

radiology, nuclear medicine & medical imaging,biology,nuclear science & technology
Comparison of Iodine-125 Seed Implantation and Pancreaticoduodenectomy in the Treatment of Pancreatic Cancer

Kai Liu,Bai Ji,Wei Zhang,Songyang Liu,Yingchao Wang,Yahui Liu

DOI: https://doi.org/10.7150/ijms.8948

2014-01-01

International Journal of Medical Sciences

Abstract:OBJECTIVE: This retrospective study compared the advantages and disadvantages of iodine-125 (125I) seed implantation and pancreaticoduodenectomy (PD) in the treatment of pancreatic cancer.METHODS: Patients with diagnosed pancreatic cancer who were treated with 125125I seed implantation (30 patients) or PD (30 patients) in our hospital were evaluated for operative time, bleeding, liver function, time to first bowel movement and normal diet, survival, and medical costs.RESULTS: Compared with patients who underwent PD, those given 125I seed implantation had significantly shorter operative time, less bleeding, higher albumin, shorter periods to bowel movement and normal diet, lower risk of complications, and lower medical costs (P < 0.001, each). The difference of bilirubin level, time to feeding, and median survival were not significant statistically between two treatment grouops.CONCLUSION: For pancreatic cancer patients for whom PD is not appropriate or who refuse PD, 125I seed implantation is a good option.

medicine, general & internal
Clinical Efficacy and Safety of Traditional Medicine Preparations Combined With Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis

Jiaqi Hu,Juling Jiang,Rui Liu,Mengqi Cheng,Guanghui Zhu,Shulin He,Bolun Shi,Yuwei Zhao,Zhongning He,Huibo Yu,Xing Zhang,Honggang Zheng,Baojin Hua

DOI: https://doi.org/10.3389/fonc.2022.828450

IF: 4.7

2022-02-23

Frontiers in Oncology

Abstract:Background Traditional medicine preparations (TMPs) combined with chemotherapy is widely used for patients with advanced pancreatic cancer (APC); however, its efficacy and safety are still unclear. The purpose of this meta-analysis was to evaluate the clinical efficacy and safety of TMPs combined with chemotherapy for the treatment of APC. Methods A systematic search of eight electronic databases for randomized controlled trials (RCTs) was conducted from inception to October 15, 2021. Tumor response was identified as primary outcome, whereas quality of life (QoL), cancer biomarkers, and adverse drug reactions (ADRs) were identified as secondary outcomes. Quality of the evidence for each outcome was evaluated by GRADE profiler. Results In total, 31 RCTs involving 1,989 individuals were included. This meta-analysis showed that TMPs combined with chemotherapy significantly improved the objective response rate (ORR) (RR=1.64, 95% CI [1.43 to 1.88], p <0.00001), disease control rate (DCR) (RR=1.29, 95% CI [1.21 to 1.38], p <0.00001), and QoL (continuous data: SMD=0.81, 95% CI [0.44 to 1.18], p <0.0001, dichotomous data: RR=1.44, 95% CI [1.22 to 1.70], p<0.0001), compared to those with chemotherapy alone. In addition, the combined treatment group also had lower levels of CA19-9 (SMD=-0.46, 95% CI [-0.90 to -0.02], p =0.04) and CEA (SMD=-0.55, 95% CI [-0.93 to -0.17], p =0.004). Moreover, TMPs reduced the ADRs during chemotherapy. Conclusion This systematic review suggests that TMPs combined with chemotherapy might be a potential option to enhance therapeutic effects and reduce ADRs during the treatment of APC. However, more high-quality randomized controlled trials with more participants are needed. Systematic Review Registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=209825 , identifier PROSPERO Number: CRD42021264938.

oncology
Efficacy and Safety of Gemcitabine Plus Erlotinib for Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis

Yuan Wang,Guangda Hu,Qianqian Zhang,Ning Tang,Jun Guo,Liyan Liu,Xiao Han,Xia Wang,Zhehai Wang

DOI: https://doi.org/10.2147/dddt.s105442

2016-01-01

Abstract:Pancreatic cancer is considered as a chemoresistant neoplasm with extremely dismal prognosis. Gemcitabine is recommended as the standard agent for locally advanced or metastatic pancreatic cancer. A series of trials have been conducted to improve the outcome of advanced pancreatic cancer with other anticancer drugs in combination with gemcitabine. Unfortunately, the designers of the clinical trials failed to improve the poor prognosis of patients with advanced pancreatic cancer. Erlotinib was the first additional drug that improved the overall survival of patients with advanced pancreatic cancer with gemcitabine. We performed this systematic review and meta-analysis to explore the efficacy and safety of the combination of gemcitabine with erlotinib (GemErlo) for patients with advanced pancreatic cancer using the currently available evidence.
A meta-analysis on the efficacy of endoscopic ultrasonography for treatment of pancreatic cancer

Min Xuan,Na Li,Chunyan Wu

DOI: https://doi.org/10.1016/j.clinsp.2024.100348

IF: 2.898

2024-01-01

Clinics

Abstract:OBJECTIVE: This study aimed to systematically evaluate the efficacy and safety of Endoscopic Ultrasonography (EUS) for the treatment of pancreatic cancer.METHODS: The PubMed, Embase, Web of Science, and Google Scholar databases were searched from the inception of the databases to June 2022. RevMan 5.3.0 software was utilized for data analysis. In total, 13 self-descriptive studies, which enrolled 382 patients, were finally included.RESULTS: It was revealed that EUS for the treatment of pancreatic cancer exhibited a lower incidence of adverse reactions (Relative Risk Ration [RR = 0.23], 95 % Confidence interval [95 % CI 0.23-0.23]), a higher success rate (RR = 0.90, 95 % CI 0.90-0.90), and a low failure rate (RR = 0.06, 95 % CI 0.06-0.06). Moreover, EUS-guided Celiac Plexus Neurolysis (EUS-CPN) not only significantly relieved pancreatic cancer patients' pain (RR = 0.83, 95 % CI 0.83-0.83), but also significantly eliminated pain in some patients (RR = 0.09, 95 % CI 0.09-0.09). The effects of EUS on pancreatic cancer treatment were satisfactory, and few adverse reactions were found.CONCLUSION: Owing to the restricted sample size in this meta-analysis, primarily consisting of descriptive studies, it was imperative to conduct more rigorously designed, multi-center, long-term follow-up, larger sample, and Randomized Controlled Trials (RCTs) to validate the findings.

medicine, general & internal

Efficacy and Safety of CT-Guided I-125 Seed Implantation for Advanced Pancreatic Cancer: A Meta-Analysis

Efficacy and Safety of CT-guided 125I Seed Implantation for Treatment of Advanced Pancreatic Cancer: a Meta-analysis

Percutaneous CT-Guided Iodine-125 Seeds Implantation for Unresectable Pancreatic Cancer

Therapeutic Effect of CT-guided 125I Seed Implantation on Advanced Lung Cancer and Pulmonary Metastatic Carcinoma

Safety and Effectiveness Analysis of Percutaneous Microwave Thermal Ablation Therapy Combined Brachytherapy for Lung Malignant Lesion

Analysis of the Efficacy of Transcatheter Arterial Infusion Chemotherapy in the Treatment of Pancreatic Carcinoma

Ultrasound-guided interstitial ~(125)I seed implantation in the treatment of locally advanced pancreatic carcinoma

Efficacy Analysis of Chemotherapy in Combination with 125I Seed Implantation for Treatment of Inoperational Pancoast Tumor

Iodine-125 Seed Implantation for Unresectable Pancreatic Carcinoma Guided by Intraoperative Ultrasound

Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma

CT-MPR Guides Percutaneous Brachytherapy Easily for Hepatic Carcinoma and Extrahepatic Metastases

Efficacy and safety of 3D printing coplanar template-assisted iodine-125 seed implantation as palliative treatment for inoperable pancreatic cancer

Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials

Evaluation of CT-guided ~(125)I Seed Implantation Combined with Transcatheter Arterial Chemoembolization in Treating Portal Vein Tumor Thrombus Associated with Hepatocellular Carcinoma

The Investigation of 125I Seed Implantation As a Salvage Modality for Unresectable Pancreatic Carcinoma.

Clinical Studies of Pancreatic Cancer Treated by Endovascular Implantation of Iodine-125 Seeds Strand

The efficacy of coaxial percutaneous iodine-125 seed implantation combined with arterial infusion chemotherapy for advanced pancreatic cancer: a randomized clinical trial

Comparison of Iodine-125 Seed Implantation and Pancreaticoduodenectomy in the Treatment of Pancreatic Cancer

Clinical Efficacy and Safety of Traditional Medicine Preparations Combined With Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis

Efficacy and Safety of Gemcitabine Plus Erlotinib for Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis

A meta-analysis on the efficacy of endoscopic ultrasonography for treatment of pancreatic cancer